Table 2.
Pts characteristics by baseline CS use, and OS HR by CS use (modified from Drakaki et al. [60])
| NSCLC (n = 862) | Melanoma (n = 742) | UC (n = 609) | ||||
|---|---|---|---|---|---|---|
| CS (n = 258) |
No CS (n = 604) |
CS (n = 182) |
No CS (n = 560) |
CS (n = 116) |
No CS (n = 493) |
|
| Stage IV at diagnosis | 74 | 61 | 34 | 29 | 42 | 35 |
| ECOG PS ≥ 2 at ICI start | 17 | 15 | 9 | 11 | 34 | 21 |
| Site of metastases | ||||||
| Brain | 26 | 19 | 31 | 21 | 5 | 2 |
| Multivariable OS, HR (95% CI), CS use vs. no CS use (reference) | ||||||
| Model 1 | 1.35 (1.12, 1.62) | 1.23 (0.97, 1.57) | 1.47 (1.14, 1.90) | |||
| Model 2 | 1.34 (1.12, 1.61) | 1.24 (0.97, 1.57) | 1.44 (1.12, 1.87) | |||
Multivariable models adjusted for age at ICI start, stage at diagnosis, race/ethnicity, ECOG PS and Charlson Comorbidity Index at ICI start; treatment sequence, brain metastases at ICI start, smoking status (NSCLC, UC), histology (NSCLC), grade (UC) in model 1 and prior steroid use in model 2
Pts patients, CS corticosteroids, NSCLC non-small cell lung cancer, UC urothelial cancer, ICI immune checkpoint inhibitors, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR hazard ratio